var data={"title":"Liothyronine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Liothyronine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6468?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=liothyronine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Liothyronine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=liothyronine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Liothyronine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709013\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Weight reduction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines, such as those used for their anorectic effects.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189046\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cytomel;</li>\n      <li>Triostat</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189047\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cytomel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189085\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Thyroid Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189051\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypothyroidism:</b> Oral: Initial: 25 mcg once daily; may increase by up to 25 mcg/day every 1 to 2 weeks; usual maintenance dose: 25 to 75 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients with cardiovascular disease:</i> Initial: 5 mcg once daily; may increase by 5 mcg/day every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients with myxedema:</i> Initial: 5 mcg once daily; increase in increments of 5 to 10 mcg/day every 1 to 2 weeks. When 25 mcg/day is reached, dosage may be increased at intervals of 5 to 25 mcg/day every 1 to 2 weeks. Usual maintenance dose: 50 to 100 mcg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion to liothyronine from thyroid (desiccated) or levothyroxine:</i> Discontinue the other medication, initiate a low dose of liothyronine, and increase gradually according to response. Liothyronine has a rapid onset of action; residual effects of other thyroid preparation may persist for the first several weeks into therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myxedema coma:</b> IV: Initial: 25 to 50 mcg; patients with known or suspected cardiovascular disease: 10 to 20 mcg; initial and maintenance dosing is based on clinical condition and response to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendation (use in combination with levothyroxine) (off-label dose):</i> Initial: 5 to 20 mcg loading dose; maintenance: 2.5 to 10 mcg every 8 hours; continue therapy as clinically indicated. Lower dosages should be considered for patients who are small, elderly, or have coronary artery disease or arrhythmia. Avoid high doses due to risks associated with high serum triiodothyronine levels (ATA [Jonklaas 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Normally, at least 4 hours should be allowed between IV doses to adequately assess therapeutic response and no more than 12 hours should elapse between doses to avoid fluctuations in hormone levels. Oral therapy should be resumed as soon as the clinical situation has been stabilized and the patient is able to take oral medication. If levothyroxine rather than liothyronine sodium is used in initiating oral therapy, the prescriber should bear in mind that there is a delay of several days in the onset of levothyroxine activity and that IV therapy should be discontinued gradually.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion to liothyronine tablets from injectable liothyronine:</i> Discontinue the injectable, initiate oral therapy at a low dosage, and increase gradually according to response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Suppression test (T<sub>3</sub>):</b> Oral: 75 to 100 mcg once daily for 7 days. Radioactive iodide uptake is determined before and after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antidepressant augmentation (off-label use):</b> Oral: Initial: 25 mcg/day; may be increased to 50 mcg/day after ~1 week based on response and tolerability (APA 2010). Dose ranges of 20 to 62.5 mcg/day have been studied in clinical trials (Altshuler 2001; Aronson 1996; Nierenberg 2006). <b>Note:</b> The duration of treatment has not been well studied (APA 2010; Cooper-Kazaz 2008). If the patient has a history of multiple episodes or significant treatment resistance, long-term maintenance treatment is reasonable if there are no symptoms of hyperthyroidism and no known cardiac disease (Rosenthal 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cadaveric organ recovery (hormonal resuscitation) (off-label use):</b> IV: Initial: 4 mcg bolus followed by a continuous infusion of 3 mcg/hour administered to the brain-dead donor who is hemodynamically unstable requiring significant vasopressor support; give concomitantly with vasopressin, methylprednisolone, and continuous regular insulin infusion (maintain blood glucose 120 to 180 mg/dL) (Rosendale 2003a; Rosendale 2003b; Rosengard 2002; SCCM/ACCP/AOPO [Kotloff 2015]; Zaroff 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of memory deficit with ECT (off-label use):</b> Oral: 50 mcg once daily administered from the day before beginning of ECT and every morning until the last session (Mohagheghi 2015). Additional data may be necessary to further define the role of liothyronine in this setting. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189070\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=liothyronine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Liothyronine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital hypothyroidism:</b> Oral: Initial: 5 mcg once daily; increase by 5 mcg every 3 to 4 days until the desired response is achieved. Usual maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 20 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 3 years of age: 50 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;3 years: Full adult dosing may be necessary; refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Therapy is maintained for life except when transient hypothyroidism is suspected; if suspected, interrupt therapy for 2 to 8 weeks after the age of 3 years to evaluate. Therapy may be discontinued if normal TSH serum levels are maintained during therapy interruption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189052\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypothyroidism: </b>Oral: 5 mcg once daily; increase by 5 mcg/day every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myxedema coma:</b> IV: Refer to adult dosing; use with caution and initiate at the low end of the dosing range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Suppression test (T<sub>3</sub>):</b> Oral: Refer to adult dosing; use with caution and initiate at the low end of dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265632\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Liothyronine undergoes substantial renal excretion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265633\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189023\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triostat: 10 mcg/mL (1 mL) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytomel: 5 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytomel: 25 mcg, 50 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mcg, 25 mcg, 50 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189008\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189027\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV use only; <b>do not administer IM or SubQ</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Intermittent IV administration:</i> Administer at a rate of 10 mcg/minute (Gahart 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Continuous IV infusion:</i> Cadaveric organ recovery (hormonal resuscitation) (off-label use): After IV bolus administration, may administer as a continuous infusion (Rosengard 2002; Zaroff 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189026\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid disorders:</b> Oral: Replacement or supplemental therapy in hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis; a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myxedema coma/precoma: </b> IV: Treatment of myxedema coma/precoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> May be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726809\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Antidepressant augmentation; Cadaveric organ recovery (hormonal resuscitation); Prevention of memory deficit with electroconvulsive therapy (ECT)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189090\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Liothyronine may be confused with levothyroxine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">T3 is an error-prone abbreviation (mistaken as acetaminophen and codeine [ie, Tylenol&reg; #3])</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189015\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Cardiovascular: Cardiac arrhythmia (6%), tachycardia (3%), hypotension (&le;2%), myocardial infarction (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Allergic skin reaction, angina pectoris, cardiac failure, fever, hypertension, phlebitis, twitching</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189030\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to liothyronine sodium or any component of the formulation; undocumented or uncorrected adrenal insufficiency; untreated thyrotoxicosis; artificial rewarming (injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Acute myocardial infarction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189012\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Treatment with glucocorticoids should precede thyroid replacement therapy in patients with adrenal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; they may be more likely to have compromised cardiovascular function. Increase dose slowly and monitor for signs/symptoms of angina.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight reduction (off-label use): <b>[US Boxed Warning]: Thyroid supplements are ineffective and potentially toxic for weight reduction.</b><b> High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299607\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189017\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9563&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apalutamide: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189019\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189034\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liothyronine has not been found to increase the risk of teratogenic or adverse effects following maternal use during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy (Stagnaro-Green 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12990097\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous thyroid hormones are minimally found in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189021\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TSH 4 to 6 weeks after treatment initiation or dose changes, 4 to 6 months after adequate replacement dose determined, followed by every 12 months thereafter (or more frequently depending on clinical situation) (Jonklaas 2014); T<sub>4</sub>; heart rate, blood pressure; clinical signs of hypo- and hyperthyroidism; TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage in primary thyroid dysfunction. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T<sub>4</sub> remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T<sub>4</sub> is needed to evaluate further increase in dosage. Free T<sub>4</sub> (not TSH) should be monitored to guide treatment in patients with central hypothyroidism (ATA/AACE [Garber 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bone mineral density (particularly with long term use in postmenopausal women).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressant augmentation (off-label use): Adults: Free T<sub>3</sub>, free T<sub>4</sub>, and TSH (baseline, recheck at 3 months, and then every 6 months to 1 year at minimum). TSH level should be at least at the lower limit of the normal range [~0.4 milliunits/ml] or below in the absence of hyperthyroid symptoms; free T<sub>3</sub> can be maintained at the upper limit of the normal range based on the severity of depressive symptoms and response to T<sub>3</sub>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189024\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">T<sub>4</sub> (thyroxine) serum concentrations: Adults: ~4 to 12 mcg/dL (SI: 51 to 154 nmol/L). <b>Note: </b>Normal range in pregnancy: ~5.5 to 16 mcg/dL (SI: ~71 to 206 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">T<sub>4</sub> free (free thyroxine; free T<sub>4</sub>) serum concentrations: Adults: 0.7 to 1.8 ng/dL (SI: 9 to 23 pmol/L).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">T<sub>3</sub> total (triiodothyronine; total T<sub>3</sub>) serum concentrations: Adults: 80 to 230 ng/dL (SI: 1.2 to 3.5 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid-stimulating hormone (TSH) serum concentrations: Adults: Varies by laboratory and assay used; refer to laboratory provided reference range. If an upper and lower limit of normal for a third generation TSH assay is not available, a reference range of 0.45 to 4.12 milliunits/L should be considered (ATA/AACE [Garber 2012]). A higher target range of 4 to 6 milliunits/L has been suggested in patients &gt;70 years (ATA [Jonklaas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subclinical hypothyroidism (elevated TSH; free T<sub>4</sub> within normal range):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe (TSH &ge;10 milliunits/L): These patients are at increased risk for heart failure and cardiovascular mortality and should be considered for treatment with L-thyroxine (ATA/AACE [Garber 2012]; ETA [Pearce 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate (TSH 4 to 10 milliunits/L): Decision for when to treat should be tailored to individual patient based on age, symptoms, and cardiovascular risk (ATA/AACE [Garber 2012]; ETA [Pearce 2013])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189011\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189029\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak response: 2 to 3 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed (95% in 4 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.75 days (Brent 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189033\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Liothyronine Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/mL (1 mL): $462.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Triostat Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/mL (1 mL): $493.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cytomel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg (100): $230.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (100): $302.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (100): $461.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Liothyronine Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg (100): $80.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (100): $105.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (100): $160.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189035\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cynomel (BF, BJ, CI, ET, FR, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, PE, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Cytomel (BB, BE, LU, NL);</li>\n      <li>Cytomel 25 (IL);</li>\n      <li>Dispon (IT);</li>\n      <li>Halotri (ES);</li>\n      <li>Iobolin (BR);</li>\n      <li>Liothyronin (NO, PL, SE);</li>\n      <li>Neo-Tiroimade (PT);</li>\n      <li>Novotiral (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>T3 (GR, PY);</li>\n      <li>Tertroxin (AU, CZ, GB);</li>\n      <li>Tetronine (KR);</li>\n      <li>Thybon Henning (DE);</li>\n      <li>Thyronine (JP);</li>\n      <li>Thyrotardin inject. (DE);</li>\n      <li>Ti-Tre (IT);</li>\n      <li>Tri-Iodo-Tironina (AR);</li>\n      <li>Trijodthyronin (AT, PL);</li>\n      <li>Trijodthyronin BC (DE);</li>\n      <li>Triyodotironina (ES);</li>\n      <li>Triyotex (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"APA.2010\"></a>American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd edition. November 2010. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11578993\"></a>Altshuler LL, Bauer M, Frye MA, et al. Altshuler Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. <i>Am J Psychiatry</i>. 2001;158(10):1617-1622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/11578993/pubmed\" target=\"_blank\" id=\"11578993\">11578993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8792761\"></a>Aronson R, Offman HJ, Joffe RT, Naylor CD. Aronson Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. <i>Arch Gen Psychiatry</i>. 1996;53(9):842-848.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/8792761 /pubmed\" target=\"_blank\" id=\"8792761 \">8792761 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23879318\"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, M&ouml;ller HJ; World Federation of Societies of Biological Psychiatry; Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/23879318/pubmed\" target=\"_blank\" id=\"23879318\">23879318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent GA, Koenig RJ. Chapter 39. Thyroid and Anti-Thyroid Drugs. In: Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18047754\"></a>Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. <i>Int J Neuropsychopharmacol</i>. 2008;11(5):685-699.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/18047754/pubmed\" target=\"_blank\" id=\"18047754\">18047754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytomel (liothyronine sodium) [prescribing information]. New York, NY: Pfizer; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytomel (liothyronine sodium) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dahlberg PA, Karlsson FA, and Wide L, &ldquo;Triiodothyronine Intoxication,&rdquo; <i>Lancet</i>, 1979, 2(8144):700.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahart BL, Nazareno AR. <i>2014 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>. 30th ed. St Louis, MO: Elsevier/Mosby; 2014:745-747.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garber KR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. <i>Endocr Pract</i>. 2012;18(6):988-1028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/23246686/pubmed\" target=\"_blank\" id=\"23246686\">23246686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22964160\"></a>Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. <i>J Psychiatr Res</i>. 2012;46(11):1406-1413.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/22964160/pubmed\" target=\"_blank\" id=\"22964160\">22964160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update. <i>Endocr Pract</i>. 2016;22(5):622-639. doi: 10.4158/EP161208.GL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/27167915/pubmed\" target=\"_blank\" id=\"27167915\">27167915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/26462967/pubmed\" target=\"_blank\" id=\"26462967\">26462967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Helfand M and Crapo LM, &ldquo;Monitoring Therapy in Patients Taking Levothyroxine,&rdquo; <i>Ann Intern Med</i>, 1990, 113(6):450-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/2143640/pubmed\" target=\"_blank\" id=\"2143640\">2143640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20080850\"></a>James SR, Ranasinghe AM, Venkateswaran R, McCabe CJ, Franklyn JA, Bonser RS. The effects of acute triiodothyronine therapy on myocardial gene expression in brain stem dead cardiac donors. <i>J Clin Endocrinol Metab</i>. 2010;95(3):1338-1343.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/20080850/pubmed\" target=\"_blank\" id=\"20080850\">20080850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo; <i>Geriatric Pharmacology</i>, Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. <i>Thyroid</i>. 2014;24(12):1670-1751. doi: 10.1089/thy.2014.0028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/25266247/pubmed\" target=\"_blank\" id=\"25266247\">25266247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25978154\"></a>Kotloff RM, Blosser S, Fulda GJ, et al. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. <i>Crit Care Med</i>. 2015;43(6):1291-1325.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/25978154/pubmed\" target=\"_blank\" id=\"25978154\">25978154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25945337\"></a>Mohagheghi A, Arfaie A, Amiri S, Nouri M, Abdi S, Safikhanlou S. Preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial. <i>Biomed Res Int</i>. 2015;2015:503918.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/25945337/pubmed\" target=\"_blank\" id=\"25945337\">25945337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16946176\"></a>Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. <i>Am J Psychiatry</i>. 2006;163(9):1519-30; quiz 1665.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/16946176/pubmed\" target=\"_blank\" id=\"16946176\">16946176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25405914\"></a>Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. <i>Transplantation</i>. 2014;98(10):1119-1127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/25405914/pubmed\" target=\"_blank\" id=\"25405914\">25405914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of subclinical hypothyroidism. <i>Eur Thyroid J</i>. 2013;2(4):215-228. doi: 10.1159/000356507.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/24783053/pubmed\" target=\"_blank\" id=\"24783053\">24783053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12605114\"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive Pharmacologic Donor Management Results in More Transplanted Organs. <i>Transplantation</i>. 2003a;75(4):482-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/12605114/pubmed\" target=\"_blank\" id=\"12605114\">12605114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12717226\"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/12717226/pubmed\" target=\"_blank\" id=\"12717226\">12717226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12243491\"></a>Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. <i>Am J Transplant</i>. 2002;2(8):701-711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/12243491/pubmed\" target=\"_blank\" id=\"12243491\">12243491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenthal LJ, Goldner WS, O'Reardon JP. T3 augmentation in major depressive disorder: safety considerations. <i>Am J Psychiatry</i>. 2011;168(10):1035-1040.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/21969047/pubmed\" target=\"_blank\" id=\"21969047\">21969047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17488392\"></a>Salim A, Martin M, Brown C, et al, &ldquo;Using Thyroid Hormone in Brain-Dead Donors to Maximize the Number of Organs Available for Transplantation,&rdquo; <i>Clin Transplant</i>, 2007, 21(3):405-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/17488392 /pubmed\" target=\"_blank\" id=\"17488392 \">17488392 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanders LR, &ldquo;Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly,&rdquo; <i>Geriatric Medicine</i>, 1990, 475-87.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sawin CT, Geller A, Hershman JM, et al, &ldquo;The Aging Thyroid. The Use of Thyroid Hormone in Older Persons,&rdquo; <i>JAMA</i>, 1989, 261(18):2653-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/2709545/pubmed\" target=\"_blank\" id=\"2709545\">2709545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stagnaro-Green A, Abalovich M, Alexander E, et al; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum, Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. <i>Thyroid</i>. 2011;21(10):1081-1125. doi: 10.1089/thy.2011.0087.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/21787128/pubmed\" target=\"_blank\" id=\"21787128\">21787128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triostat (liothyronine sodium) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; received August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watts NB, &ldquo;Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine,&rdquo; <i>Arch Intern Med</i>, 1989, 149(2):309-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/2644903/pubmed\" target=\"_blank\" id=\"2644903\">2644903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12176957\"></a>Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus Conference Report: Maximizing Use of Organs Recovered from the Cadaver Donor: Cardiac Recommendations: March 28-29, 2001, Crystal City, Va. <i>Circulation</i>. 2002;106(7):836-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-drug-information/abstract-text/12176957/pubmed\" target=\"_blank\" id=\"12176957\">12176957</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9563 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709013\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189046\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F189047\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F189085\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F189051\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F189070\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F189052\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16265632\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16265633\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189023\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F189008\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F189027\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F189026\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726809\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189090\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189015\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189030\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189012\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299607\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189017\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F189019\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F189034\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12990097\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F189021\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F189024\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189011\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F189029\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189033\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189035\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9563|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=liothyronine-patient-drug-information\" class=\"drug drug_patient\">Liothyronine: Patient drug information</a></li><li><a href=\"topic.htm?path=liothyronine-pediatric-drug-information\" class=\"drug drug_pediatric\">Liothyronine: Pediatric drug information</a></li></ul></div></div>","javascript":null}